1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING FOCUS ON PRECISION MEDICINE
6.1.2 INCREASING INCIDENCE OF BRAIN CANCER
6.2 MARKET RESTRAINTS
6.2.1 VERY FEW BRAIN CANCER SPECIFIC DRUGS
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY CANCER TYPE
7.1.1 GLIOMA
7.1.1.1 ASTROCYTOMA
7.1.1.2 OLIGODENDROGLIOMA
7.1.1.3 EPENDYMOMA
7.1.1.4 CHOROID PLEXUS PAPILLOMA
7.1.2 MENINGIOMA
7.1.3 PITUITARY ADENOMA
7.1.4 SCHWANNOMAS
7.1.5 MEDULLOBLASTOMA
7.2 BY THERAPEUTICS
7.2.1 RADIATION THERAPY
7.2.1.1 X-RAY THERAPY
7.2.1.2 GAMMA-RAY THERAPY
7.2.2 CHEMOTHERAPY
7.2.2.1 SYSTEMIC CHEMOTHERAPY
7.2.2.2 LOCAL CHEMOTHERAPY
7.2.3 TARGETED THERAPY
7.3 BY GEOGRAPHY
7.3.1 NORTH AMERICA
7.3.1.1 US
7.3.1.2 CANADA
7.3.1.3 MEXICO
7.3.2 EUROPE
7.3.2.1 FRANCE
7.3.2.2 UK
7.3.2.3 GERMANY
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF EUROPE
7.3.3 ASIA-PACIFIC
7.3.3.1 INDIA
7.3.3.2 CHINA
7.3.3.3 JAPAN
7.3.3.4 AUSTRALIA
7.3.3.5 SOUTH KOREA
7.3.3.6 REST OF APAC
7.3.4 MIDDLE EAST AND AFRICA
7.3.4.1 GCC
7.3.4.2 SOUTH AFRICA
7.3.4.3 REST OF MIDDLE EAST AND AFRICA
7.3.5 SOUTH AMERICA
7.3.5.1 BRAZIL
7.3.5.2 ARGENTINA
7.3.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES
9. KEY PLAYERS
9.1 F. HOFFMAN LA-ROCHE LTD.
9.2 PFIZER
9.3 MERCK
9.4 BRISTOL MYERS SQUIBB CO.
9.5 NOVARTIS
9.6 GLAXOSMITHKLINE PLC
9.7 BAYER AG
9.8 OTHERS
10. FUTURE OUTLOOK OF THE MARKET

F. HOFFMAN LA-ROCHE LTD.
PFIZER
MERCK
BRISTOL MYERS SQUIBB CO.
NOVARTIS
GLAXOSMITHKLINE PLC
BAYER AG